Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-4

Assuming sales remain static for the second quarter at 1.5M for the Mute sales,
And most of the 1.9 rev for rhino swab is recognized next quarter, then 2nd half should come in at a very respectful 2.3M.
That would be 15% up on Q2 last year.
That could be considered a base line, Q2 as generally been better for Mute sales and we can only hope that rhino sales will continue to build.
So next quarter should see a substantial improvement in line with past QonQ growth.
That doesnt solve the cash situation but I was pleased to see costs coming down.
I would like to see more contracts signed for Rhino swab as they have stated that there are other parties interested.
I'm still of the belief that the Rhino swab is a superior product that will find its place in the market.
But I can also understand there's an element of distrusts over past performance.

I'll wait and see if next quarter confirms ongoing sales in Rhino swab.